Abstract
Opioids are used to treat pain, but despite their effectiveness, they possess several side effects such as respiratory depression, tolerance and physical dependence. Cebranopadol has been evaluated as a solution to this problem. The compound acts on the mu opioid receptor and the no-ciceptin/orphanin receptor and these receptors co-activation can reduce opioid side-effects without compromising analgesia. In the present review, we have compiled information on the effects of cebranopadol, its pharmacokinetics, and clinical trials involving cebranopadol, to further explore its promise in pain management.
Author supplied keywords
Cite
CITATION STYLE
Ziemichod, W., Kotlinska, J., Gibula-Tarlowska, E., Karkoszka, N., & Kedzierska, E. (2022, July 1). Cebranopadol as a Novel Promising Agent for the Treatment of Pain. Molecules. MDPI. https://doi.org/10.3390/molecules27133987
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.